Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

• ClinicalTrials.gov Identifier: NCT01769508
• Recruitment Status: Terminated
• First Posted: January 16, 2013
• Results First Posted: April 27, 2016
• Last Update Posted: June 13, 2016
• Sponsor: SCRI Development Innovations, LLC
• Collaborator: GlaxoSmithKline
• Information provided by (Responsible Party): SCRI Development Innovations, LLC

Study Description

Brief Summary:

With improvements in response rate and survival seen for HER2 positive patients treated with HER2 blockade in the metastatic setting, the use of HER2 blockade in the neoadjuvant setting to increase antitumor effect shows promise. Patients with previously untreated localized HER2 positive esophageal, GE junction and gastric adenocarcinomas will be enrolled. Patients meeting all inclusion/exclusion criteria will receive neoadjuvant treatment with concurrent chemotherapy and radiation therapy beginning on day 1 of treatment. During the lead-in safety portion, the optimal dose of lapatinib will be determined.

Condition or disease	Intervention/treatment	Phase
HER2 Positive Esophagogastric Cancer	Drug: 5-Fluorouracil; Drug: Oxaliplatin; Drug: Lapatinib; Radiation: Radiation Therapy	Phase 2

Detailed Description:

This is an open-label, non-randomized, Phase II study with a lead-in safety cohort. The study will evaluate the combination of 5-Fluorouracil, Oxaliplatin and Lapatinib with radiation therapy as neoadjuvant treatment for patients with previously untreated localized HER2 positive esophagogastric adenocarcinomas. Approximately 12 patients will be enrolled in the lead-in cohort to evaluate the safety of the combination. Following the lead-in cohort, Phase II will commence and up to 30 additional patients may be treated. The starting doses will be administered as follows:

5-FU 225 mg/mg2 continuous intravenous (IV) infusion Days 1 - 42 during XRT; Oxaliplatin 85 mg/m2 Days 1, 15 and 29, given by IV infusion, per institutional standard; Lapatinib Continuous PO daily dosing during XRT (final dose determined during lead-in cohort).

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 12 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Study With Lead-in Safety Cohort of 5-Fluorouracil, Oxaliplatin and Lapatinib in Combination With Radiation Therapy as Neoadjuvant Treatment for Patients With Localized HER2 Positive Esophagogastric Adenocarcinomas
• Study Start Date: February 2013
• Actual Primary Completion Date: February 2014
• Actual Study Completion Date: February 2015

Arms and Interventions

Arm

Intervention/treatment

Experimental: Combined Therapy; Combined Modality Treatment of Radiation therapy, 5-Fluorouracil, Oxaliplatin and Lapatinib followed by Surgery

Drug: 5-Fluorouracil; 5-FU, 225 mg/m2 IVCI, during XRT.; Other Name: Combined Modality Treatment; Drug: Oxaliplatin; Oxaliplatin, 85 mg/m2 IV, Days 1, 15, 29.; Other Name: Combined Modality Treatment; Drug: Lapatinib; Lapatinib, Continuous PO daily dosing during XRT, dose determined during lead in portion; Other Name: Combined Modality Treatment; Radiation: Radiation Therapy; Radiation therapy, 50.4 Gy (1.8 Gy/day or 28 fractions) M-F, Weeks1-6

Outcome Measures

Primary Outcome Measures :

1. Pathologic Complete Response Rate (pCR Rate) [ Time Frame: 18 months ]
   Defined as the absence of invasive tumor in esophagogastric and lymph node tissue removed at time of surgery, as judged by the local pathologist. An improvement in pCR rate from 30 percent (historical) to 50 percent is the primary efficacy endpoint.
2. Safety and Optimal Dose of Regimen [ Time Frame: 18 months ]
   An additional primary objective is to evaluate the safety and optimal dose of lapatinib when added to 5-FU, oxaliplatin and radiation therapy.

Secondary Outcome Measures :

1. Progression Free Survival (PFS) [ Time Frame: 18 months ]
   The Percentage of Patients Who Experience an Objective Benefit From Treatment. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
2. Toxicity Profile for Treated Patients [ Time Frame: 18 months ]
   Defined as the frequency of adverse events for patients who received at least one dose of study treatment, and assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0.
3. Time to Progression (TTP) [ Time Frame: 18 months ]
   Time to progression is defined as the time between day 1 cycle 1 and time to first documented disease progression. Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
4. Overall Survival (OS) [ Time Frame: 18 months ]
   The Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Histologically confirmed Stage I, II, or III adenocarcinoma of the esophagus (lower ⅓), GE junction, or gastric cardia.
• Clinical stage I, II, or III as assessed by required baseline staging. In addition, patients with celiac node involvement (stage IVa) are eligible.
• Patients must be surgical candidates based on stage and location of disease as well as other medical conditions and risk factors.
• Positive HER2 status (overexpression and/or amplification of HER2 in primary tumor) as defined by FISH (HER2 FISH positivity).
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.
• Patient must be able to swallow and absorb oral medication.
• Patients must have an indwelling central venous access catheter.
• Adequate hematologic, renal, and hepatic function:
• Known brain or leptomeningeal metastases.
• Male patients willing to use adequate contraceptive measures.
• Female patients who are not of child-bearing potential, and female patients of child-bearing potential who agree to use adequate contraceptive measures, who are not breastfeeding, and who have a negative serum or urine pregnancy test within 72 hours prior to start of treatment.
• Life expectancy ≥ 12 weeks.
• Age ≥18 years of age.
• Willingness and ability to comply with trial and follow-up procedures.
• Ability to understand the nature of this trial and give written informed consent.

Exclusion Criteria:

• Patients with evidence of distant metastases are ineligible, as are patients who are not potential surgical candidates based on location or extent of local disease. Patients with celiac nodal disease (Stage IVa) will be allowed on study.
• Previous anti-cancer treatment for esophageal, GE junction, or gastric cancer.
• Any other investigational agents within the 28 days prior to day 1 of the study.
• Known active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment).
• Concurrent treatment with drugs known to be strong inhibitors or inducers of isoenzyme CYP3A that cannot be discontinued or switched to different medication prior to starting study drug.
• Concurrent use of St. John's wort and grapefruit /grapefruit juice ≤7 days prior to starting study drug is not allowed.
• Ongoing treatment with full-dose warfarin or its equivalent. Prophylactic treatment with 1 mg daily of warfarin and/or low molecular weight heparin is allowed.
• History of any other disease, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of a novel regimen, or that might affect interpretation of the results of this study or render the subject at high-risk for treatment complications.
• Active gastrointestinal (GI) disease or other condition that in the opinion of the investigator will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy (e.g. ulcerative disease, uncontrolled nausea, or vomiting).
• Poorly controlled or clinically significant atherosclerotic vascular disease
• A serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
• Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B (HBV) or Hepatitis C (HCV).
• Presence of other active cancers, or history of treatment for invasive cancer ≤5 years. Patients with stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e. non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.
• Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
• Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.

Contacts and Locations

Locations

United States, Florida

Florida Cancer Specialists - South

Fort Myers, Florida, United States, 33916

Florida Hospital Cancer Institute

Orlando, Florida, United States, 32804

Woodlands Medical Specialists

Pensacola, Florida, United States, 32503

Florida Cancer Specialists-North

St. Petersburg, Florida, United States, 33705

United States, Georgia

Northeast Georgia Medical Center

Gainesville, Georgia, United States, 30501

United States, Michigan

Grand Rapids Oncology Program

Grand Rapids, Michigan, United States, 49503

United States, Ohio

Oncology Hematology Care

Cincinnati, Ohio, United States, 45242

United States, Tennessee

Chattanooga Oncology and Hematology Associates

Chattanooga, Tennessee, United States, 37404

Tennessee Oncology

Nashville, Tennessee, United States, 37203

Sponsors and Collaborators

SCRI Development Innovations, LLC

GlaxoSmithKline

Investigators

• Study Chair: Johanna C Bendell, MD; SCRI Development Innovations, LLC

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Shepard G, Arrowsmith ER, Murphy P, Barton JH Jr, Peyton JD, Mainwaring M, Blakely L, Maun NA, Bendell JC. A Phase II Study with Lead-In Safety Cohort of 5-Fluorouracil, Oxaliplatin, and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2-Positive Esophagogastric Adenocarcinomas. Oncologist. 2017 Oct;22(10):1152-e98. doi: 10.1634/theoncologist.2017-0186. Epub 2017 Aug 1.

• Responsible Party: SCRI Development Innovations, LLC
• ClinicalTrials.gov Identifier: NCT01769508
• Other Study ID Numbers: SCRI GI 166
• First Posted: January 16, 2013
• Results First Posted: April 27, 2016
• Last Update Posted: June 13, 2016
• Last Verified: May 2016

Keywords provided by SCRI Development Innovations, LLC:

Esophagogastric Adenocarcinoma; 5-Fluorouracil; Oxaliplatin; Lapatinib; Radiation Therapy; Surgery

Additional relevant MeSH terms:

Fluorouracil; Oxaliplatin; Lapatinib; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Protein Kinase Inhibitors; Enzyme Inhibitors